Abstract 1877P
Background
After completion of curative cancer treatment patients enter the re-entry phase, which is characterized by the difficult task to pick up life again. In the re-entry patients face existential concerns, besides physical and psychosocial concerns. Finding meaning and purpose in this new situation may help in dealing with existential concerns. More insight is needed in the existential concerns and the meaning-making process in order to support patients in the re-entry phase.
Methods
We conducted 6 focus groups with 16 patients (5 patients with melanoma and 11 with breast cancer) during the re-entry phase, defined as the point from completion of treatment (after surgical treatment and adjuvant systemic treatment, except for hormonal therapy) up to 18 months in remission. A thematic content analysis was performed by two researchers.
Results
In general, patients experienced existential concerns regarding their worldview, inner posture, values and the future. In addition, patients with melanoma struggled with trust and responsibility for their health; patients with breast cancer struggled with relationships and identity. Outcomes of the meaning-making process identified were: meaning is affected and gives distress, existing sources of meaning are helpful, search for meaning or new meaning has been found. These outcomes were found at the beginning as well as further into the re-entry, however during the re-entry the focus of the meaning-making process shifted from the disease to (picking up) life.
Conclusions
The transition from being a patient to picking up daily life in the re-entry phase involves dealing with existential concerns causing distress. Patients use existing sources of meaning, search for new meaning or have found new meaning in order to deal with these existential concerns and distress. A meaning-centered intervention increasing patients awareness of their personal sources of meaning might strengthen their meaning-making process and can help in dealing with existential concerns.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Visser and L. Post.
Funding
Novartis b.v.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05